Industry news

Lilly once again achieved success! The strongest weight loss drug with three targets – Retatrutide


Retatrutide is a triple agonist of GCG/GIP/GLP-1 receptor developed by Lilly. In the phase II clinical trial for obese people without diabetes, Retatrutide helped obese people lose 24.2% of their weight (once a week, 12mg each time, lasting for 48 weeks). It is the best effect of drug weight reduction so far. In addition, Retaglutide is also associated with improvements in blood pressure, blood lipids, and blood sugar.

In June 2022, the FDA approved Semaglutide, developed by Novo Nordisk, as a weight loss drug. The drug quickly became popular worldwide that year. It is a GLP-1 receptor (GLP-1R) agonist. In previous clinical trials, Semaglutide had a weight loss effect of 15% in obese patients (injected once a week, 2.4mg each time, for 68 weeks).

In July 2022, Lilly published the results of a phase 3 clinical trial of its developed GIPR/GLP-1R dual agonist Tirzepatide. The average weight loss of participants could reach 22.5% (once a week, 15mg each time, for 72 weeks). This effect not only exceeds the weight loss effect of semaglutide in Phase 3 clinical trials, but also sets a new record for weight loss through medication.

In less than a year, Lilly once again broke its own record for drug weight loss.

On June 26, 2023, Lilly published a clinical research paper in the New England Journal of Medicine (NEJM). In this phase 2 clinical trial, the GCGR/GIPR/GLP-1R triple agonist Retatrutide achieved a powerful weight loss effect. It helps obese individuals lose 24.2% of their weight (once a week, 12mg each time, for 48 weeks). Retatrutide is the best drug weight loss effect achieved so far.


Leave a Reply

Your email address will not be published. Required fields are marked *